Literature DB >> 16257329

The end of beta blockers for uncomplicated hypertension?

D Gareth Beevers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16257329     DOI： 10.1016/S0140-6736(05)67575-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

1.  Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.

Authors:  Nadia Khan; Finlay A McAlister
Journal:  CMAJ       Date:  2006-06-06       Impact factor: 8.262

2.  Highlights and summary of the 2006 Canadian Hypertension Education Program recommendations.

Authors:  R M Touyz
Journal:  Can J Cardiol       Date:  2006-05-15       Impact factor: 5.223

Review 3.  The latest generation of beta-blockers: new pharmacologic properties.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

Review 4.  Treatment of isolated systolic hypertension.

Authors:  Gordon S Stokes
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 5.  Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies.

Authors:  Goran Koracevic; Sladjana Micic; Milovan Stojanovic; Miloje Tomasevic; Tomislav Kostic; Radmila Velickovic Radovanovic; Dragan Lovic; Dragan Djordjevic; Miomir Randjelovic; Maja Koracevic; Zaklina Ristic
Journal:  Hypertens Res       Date:  2020-05-07       Impact factor: 3.872

Review 6.  Desirable therapeutic characteristics of an optimal antihypertensive agent.

Authors:  Lisa Mustone Alexander
Journal:  Drugs       Date:  2006       Impact factor: 9.546

7.  Comparative effectiveness of 2 β-blockers in hypertensive patients.

Authors:  Emily D Parker; Karen L Margolis; Nicole K Trower; David J Magid; Heather M Tavel; Susan M Shetterly; P Michael Ho; Bix E Swain; Patrick J O'Connor
Journal:  Arch Intern Med       Date:  2012-10-08

8.  Measuring healthcare outcomes--a race to utopia?

Authors:  Shahirose Jessani; Joseph Tomson
Journal:  J R Soc Med       Date:  2006-10       Impact factor: 18.000

Review 9.  Clinical profile of eprosartan: a different angiotensin II receptor blocker.

Authors:  P J Blankestijn; H Rupp
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-10

10.  Does atenolol differ from other beta-adrenergic blockers?

Authors:  Ivar Aursnes; Jan-Bjørn Osnes; Ingunn Fride Tvete; Jørund Gåsemyr; Bent Natvig
Journal:  BMC Clin Pharmacol       Date:  2007-05-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.